Rubius Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 27, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. RUBY, a biotechnology company developing an entirely new class of allogeneic cellular therapies, announced today that Pablo J. Cagnoni, M.D., chief executive officer, will present at the 37^th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 7, 2019, at 9:00 a.m. PT.

A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.

About Rubius Therapeutics
Rubius Therapeutics is a biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company's proprietary RED PLATFORM^® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready-to-use allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius' initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction. For more information, visit www.rubiustx.com, or follow us on Twitter and LinkedIn.

Contacts:
Lori Melançon
Vice President, Corporate Communications and Investor Relations
+1 (617) 229-6122
lori.melancon@rubiustx.com

Media Contact: 
Dan Budwick
1AB, Inc.
+1 (973) 271-6085
dan@1abmedia.com